Nafissi Nahid, Najafi Fatemeh, Jafarzadeh Alireza, Behrangi Elham, Roohaninasab Masoumeh, Rahimi Seyyedeh Tahereh, Salehi Sepideh, Jafari-Nasirmahalleh Amir, Hoseini Nazanin, Goodarzi Azadeh
Department of Surgery, Rasool Akram Medical Complex Research Development, School of Medicine, IUMS, Tehran, Iran.
Breast Health & Cancer Research Center, IUMS, Tehran, Iran.
J Cosmet Dermatol. 2025 Jun;24(6):e70261. doi: 10.1111/jocd.70261.
Wound healing is a complex process encompassing four main stages: hemostasis, inflammation, cell proliferation, maturation, and differentiation. Timolol (TM) may influence these stages, particularly re-epithelialization. This study aims to evaluate the 1-month effects of timolol on acute surgical wounds in post-mammoplasty patients.
To investigate the efficacy of topical timolol in improving postoperative breast scars, aiming to guide future treatment protocols and prescriptions.
A total of 12 patients who underwent bilateral mammoplasty were enrolled in this double-blind randomized clinical trial. Treatment commenced 48 h post-surgery; one breast was treated with 0.5% timolol eye drops, while the contralateral breast received distilled water (control). Patients were advised to minimize sun exposure and pressure on the treated area, and no additional oral or topical medications were prescribed. Cleansing with a prescribed cleanser occurred every 3 days. Cosmetic assessments were conducted by a specialist at 10 and 30 days post-surgery using a 10-point Likert scale. Data were analyzed using two-way repeated measures ANOVA.
Timolol significantly reduced erythema over time (Interaction, p < 0.0001; Treatment, p = 0.02), with an average decrease of 5.38 points (95% CI: 4.22-6.55) compared to 4.41 points (95% CI: 3.83-5) for placebo. The difference in reduction was 0.972 points (95% CI: 0.18-1.7). A significant improvement in the aesthetic appearance of the breast was also noted (Interaction, p < 0.0001; Treatment, p = 0.015), with timolol enhancing the aesthetic score by approximately 5.5 points (95% CI: 4.9-6.2) versus 4.58 points (95% CI: 3.4-5.7) for the placebo. Overall, timolol improved the aesthetic score by 0.972 points (95% CI: 0.23-1.7) more than the placebo.
Topical application of 0.5% timolol significantly improved the aesthetic appearance and reduced erythema of post-mammoplasty breast scars over a 1-month period. The results demonstrate a measurable clinical benefit, with statistically significant differences favoring timolol over placebo. These findings suggest that early intervention with topical timolol may offer a safe, effective, and non-invasive option for optimizing scar outcomes in surgical patients.
伤口愈合是一个复杂的过程，包括四个主要阶段：止血、炎症、细胞增殖、成熟和分化。噻吗洛尔（TM）可能会影响这些阶段，尤其是再上皮化过程。本研究旨在评估噻吗洛尔对乳房成形术后患者急性手术伤口的1个月效果。
研究外用噻吗洛尔改善术后乳房瘢痕的疗效，旨在指导未来的治疗方案和处方。
本双盲随机临床试验共纳入12例接受双侧乳房成形术的患者。术后48小时开始治疗；一侧乳房用0.5%噻吗洛尔滴眼液治疗，而对侧乳房用蒸馏水（对照）治疗。建议患者尽量减少阳光照射和对治疗区域的压力，且未开其他口服或外用药物。每3天用规定的清洁剂清洗一次。术后10天和30天由一名专家使用10分制李克特量表进行美容评估。数据采用双向重复测量方差分析。
随着时间的推移，噻吗洛尔显著减轻了红斑（交互作用，p<0.0001；治疗，p=0.02），平均下降5.38分（95%CI：4.22-6.55），而安慰剂为4.41分（95%CI：3.83-5）。减少量的差异为0.972分（95%CI：0.18-1.7）。乳房的美学外观也有显著改善（交互作用，p<0.0001；治疗，p=0.015），噻吗洛尔使美学评分提高约5.5分（95%CI：4.9-6.2），而安慰剂为4.
